Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age

PHASE3

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Due to COVID19 hospital admissions by patients with moderate-severe bronchiolitis have drastically decreased from 02/2020 to date. Moreover, many centers that had initially joined the study project had great difficulties in the activation phase

Conditions

Bronchiolitis, Viral

Interventions

DRUG: Curosurf 80Mg/Ml Intratracheal Suspension
OTHER: Ambient Air

Sponsor

Azienda Ospedaliera Universitaria Integrata Verona